High Risk Anatomy Challenges ISCHEMIA Outcomes

According to this recent analysis published in JAHA, patients with stable Ischemic heart disease and high-risk anatomy benefit from revascularization at long term vs. the conservative treatment. 

Ischemia

This goes against the study presented by Reynolds H et al at AHA 2020. Dr. Reynold’s was a sub-study of the ISCHEMIA trial which had observed that even though anatomical complexity impacts prognosis, it cannot be modified by revascularization. 

The ISCHEMIA, published in NEJM, and all its sub studies, came to question everything we used to believe about chronic ischemic cardiomyopathy.  However, more and more studies shed light on the recommended strategies. 

9016 patients with stable ischemic heart disease and high-risk anatomy where included (3 vessels with >70% lesion, left main with >50% lesion or a combination of both).

The primary end point of all cause death or acute myocardial infarction was compared between patients receiving revascularization and those treated conservatively.


Read also: Diabetes and Peripheral Vascular Disease: Old Drugs, New Evidence.


5487 (61%) of patients received CABG (n=3312) or PCI (n=2175), whereas the remaining 3529 (39%) were managed conservatively.

Revascularization was associated with reduced MI rate and all cause rate. In addition, it was associated with longer life expectancy compared against the conservative treatment (p<0.001 for all points). 

Reduced events rate was similar between CABG (HR 0.64, CI 95% 0.59 to 0.70, p<0.001) and PCI (HR 0.61; CI 95% 0.57 to 0.66; p<0.001).

Conclusion

Revascularization in patient with stable ischemic heart disease and high-risk anatomy improves prognosis at long term compared against the conservative treatment. Coronary anatomy should be considered before recommending revascularization to treat these patients. 

JAHA-120-018104

Original Title: Long-Term Clinical Outcomes Following Revascularization in High-Risk Coronary Anatomy Patients With Stable Ischemic Heart Disease.

Reference: Kevin R. Bainey et al. J Am Heart Assoc. 2021;10:e018104.  DOI: 10.1161/JAHA.120.018104.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....